trending Market Intelligence /marketintelligence/en/news-insights/trending/b3cta6i13wd0fi6j-3pugg2 content esgSubNav
In This List

LexaGene names CFO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


LexaGene names CFO

LexaGene Holdings Inc. appointed Jeffrey Mitchell as its CFO.

Mitchell succeeds Zula Kropivnitski at the Vancouver, British Columbia-based biotechnology company.

Mitchell was previously controller and director of finance at Palomar Medical Technologies Inc.

"Bringing Jeff onboard is part of our strategy to make LexaGene a [U.S.]-focused company. Jeff will work out of the Massachusetts headquarters and his experience in global financial operations and executive management for medical device, consumer product, and manufacturing companies will be of great value for LexaGene," the company's CEO, Jack Regan, said in a statement.